Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing

This publication has 49 references indexed in Scilit:

• Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
  Cancer Discovery, 2017
• Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
  New England Journal of Medicine, 2016
• Validation of International Classification of Diseases coding for bone metastases in electronic health records using technology-enabled abstraction
  Clinical Epidemiology, 2015
• A global reference for human genetic variation
  Nature, 2015
• Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report
  Frontiers in Oncology, 2015
• Integrative Clinical Genomics of Advanced Prostate Cancer
  Cell, 2015
• Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
  Journal of Clinical Oncology, 2013
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
  Cancer Research, 2012
• Resistance to therapy caused by intragenic deletion in BRCA2
  Nature, 2008
• Developmental Studies of Brca1 and Brca2 Knock-Out Mice
  Journal of Mammary Gland Biology and Neoplasia, 1998